Drug intelligence / Profile preview

Calcilate

Development stage: Unknown
Lead developer: Achilles Healthcare
Modality: Small Molecules
Administration: Oral

Overview

**Calcilate** is an oral fixed-dose calcium and active vitamin D formulation marketed by Achilles Healthcare. Each tablet contains calcium citrate malate 1250 mg and calcitriol 0.25 mcg. Calcium citrate malate supplies elemental calcium for skeletal mineralization, while calcitriol activates the vitamin D receptor to increase intestinal calcium absorption and support calcium-phosphate homeostasis. It is used for calcium supplementation and bone-health indications, including calcium deficiency and osteoporosis.

Brand names: Calcilate
Other names: calcium citrate malate + calcitriol

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on Calcilate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calcilate.

Explore the full profile